Skip to main content

Table 3 Survival of patients grouped by the VTS score

From: Predicting survival in melanoma patients treated with concurrent targeted- or immunotherapy and stereotactic radiotherapy

VTS score

n = 110

median OS (months)

logrank pairwise

0–1

46

5.1

vs. 1.5: 0.001

vs. 2: 0.0001

1.5

36

18.9

vs. 2: 0.03

2

28

34.5

 
  1. Abbreviations: VTS Volume-timing-systemic therapy, OS Overall survival
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us